TEPLIZUMAB-MZWV

Teplizumab-mzwv Overview

Teplizumab-mzwv is a groundbreaking prescription medication utilized primarily within Endocrinology. As an anti-CD3 directed monoclonal antibody, it is the first disease-modifying therapy designed to alter the immune system’s attack on the pancreas in patients with Type 1 diabetes.

It is indicated to delay the onset of Stage 3 (clinical) Type 1 diabetes in adults and pediatric patients aged 8 years and older who currently have Stage 2 Type 1 diabetes. Stage 2 means the patient has abnormal blood sugar levels and multiple diabetes-related autoantibodies, but does not yet require insulin injections.

What Is It and How Does It Work?

Teplizumab-mzwv is a humanized monoclonal antibody that targets specific immune cells in the body to stop them from destroying the pancreas.

It works by directly modulating the immune system:

• Targeting T-Cells: In Type 1 diabetes, the body’s own immune cells (T-cells) mistakenly attack and destroy the insulin-producing beta cells in the pancreas. Teplizumab binds specifically to a protein called CD3 on the surface of these T-cells.
• Immune Modulation: By binding to CD3, the medication deactivates the aggressive T-cells that are attacking the pancreas while simultaneously increasing the proportion of “regulatory” T-cells, which help calm the immune system down.
• Preserving Beta Cells: By halting the autoimmune attack, the medication protects the remaining beta cells, allowing the pancreas to continue producing its own insulin for a significantly longer period.

Is It FDA Approved?

Yes. Teplizumab-mzwv is a fully evaluated and FDA-approved medication.

What Is It Used For?

Federal health regulators have authorized this medication for the following specific indication:

• Type 1 Diabetes (Stage 2): Indicated to delay the onset of Stage 3 Type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 Type 1 diabetes.

Before Taking This Medication: Contraindications & Precautions

Who Should Not Take This Medication?

• Patients with active serious infections (the medication suppresses the immune system and can make infections much worse).
• Patients who have recently received live or live-attenuated vaccines.
• Patients who have abnormal baseline liver enzymes or dangerously low white blood cell counts prior to starting therapy.
• Patients with a known severe hypersensitivity to teplizumab-mzwv or any of its inactive ingredients.

Pregnancy & Breastfeeding

Teplizumab-mzwv may cause fetal harm based on its mechanism of action. Women of childbearing potential should use effective contraception during the 14-day treatment course and for at least 30 days after the last dose. It is not known if the drug is present in human breast milk; a decision should be made to either discontinue nursing or not administer the drug.

Tell Your Doctor Before Taking It

Inform your endocrinologist if you have a history of frequent infections, liver disease, or if you are pregnant or planning to become pregnant. Disclose all current medications and provide a complete history of your recent immunizations, as your vaccine schedule may need to be adjusted before starting therapy.

Dosage & Administration

Teplizumab-mzwv must be administered by a healthcare professional in a clinical setting equipped to monitor and manage potential infusion-related reactions.

Standard Dosing

The medication is supplied as an injection in single-dose vials.

• 14-Day Course: It is administered once daily for exactly 14 consecutive days.
• Dose Escalation: The daily dose is calculated based on the patient’s body surface area (BSA). To minimize side effects, the dosage is stepped up gradually over the first 5 days, reaching the maximum daily maintenance dose from day 6 through day 14.

How It Is Administered

• Intravenous Infusion: The medication is administered via an IV infusion over a minimum of 30 minutes each day.
• Pre-Medication: To prevent Cytokine Release Syndrome and nausea, patients are given pre-medications (such as an NSAID like ibuprofen, an antihistamine, and an anti-nausea drug) before the infusion every single day for the first 5 days, and as needed thereafter.

Clinical Efficacy

The FDA approval of Tzield was based on a landmark clinical trial involving patients with Stage 2 Type 1 diabetes. In this trial, a single 14-day course of teplizumab significantly delayed the median time to a clinical Type 1 diabetes diagnosis (Stage 3). Patients receiving the medication remained free of Stage 3 diabetes for a median of 50 months, compared to just 25 months for those receiving a placebo—effectively delaying the need for lifelong insulin therapy by an average of two years.

Side Effects & Safety Profile

Because teplizumab-mzwv suppresses specific immune cells to protect the pancreas, its side effects are primarily tied to the immune system and inflammatory responses.

Common Side Effects

• Lymphopenia: A significant drop in lymphocytes (a type of white blood cell). This occurs in almost all patients but typically recovers a few weeks after the 14-day treatment ends.
• Rash (often mild and resolves on its own).
• Headache.
• Nausea and fatigue.

Serious Adverse Events

• Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause high fever, muscle/joint pain, severe nausea, and liver enzyme spikes. This usually happens within the first 5 days of treatment.
• Serious Infections: Due to the temporary drop in white blood cells, patients are at a higher risk for bacterial and viral infections.
• Severe Hypersensitivity Reactions: Allergic reactions, including anaphylaxis, can occur during the infusion.

Managing Side Effects

Taking all prescribed pre-medications (like ibuprofen and antihistamines) is critical to preventing CRS and infusion reactions. If a severe reaction occurs during the IV drip, the healthcare provider will slow down or temporarily pause the infusion.

Drug Interactions & What to Avoid

Key Interactions

• Live Vaccines: Avoid entirely. Live-attenuated vaccines should not be given within 8 weeks prior to treatment, during treatment, or up to 52 weeks after treatment (until your white blood cells fully recover).
• Inactivated (Killed) Vaccines: Should be administered at least 2 weeks prior to starting the 14-day infusion course to ensure they are effective.
• Other Immunosuppressants: Concurrent use of other medications that suppress the immune system is not recommended, as it can compound the risk of severe infections.

Food & Alcohol

There are no specific food interactions. However, patients should stay well-hydrated during the 14-day infusion course. Limit alcohol consumption to avoid additional stress on the liver, as the medication can temporarily elevate liver enzymes.

Missed Dose, Overdose & Storage

Missed Dose

Because this medication is administered daily in a clinical setting, missing a dose disrupts the strict 14-day regimen. If you miss a scheduled infusion appointment, contact your doctor immediately. They will determine how to adjust your remaining infusion schedule.

Overdose

Overdose is highly unlikely since the drug is prepared and administered strictly by medical professionals. If an overdose occurs, the patient will be monitored closely in the clinical facility for signs of severe CRS or profound immune suppression, and treated supportively.

Storage Instructions

Vials must be stored in the refrigerator between 2°C and 8°C (36°F and 46°F) in their original carton to protect them from light. Do not freeze and do not shake the vials. The medication will be stored and handled exclusively by the pharmacy and medical staff.

Patient Management & Guidelines

Tests Before & During Treatment

• Complete Blood Count (CBC): Checked before starting and routinely during the 14 days to monitor for severe drops in white blood cells (lymphopenia).
• Liver Function Tests: Blood tests to check ALT, AST, and bilirubin levels are required before and during treatment to monitor for liver stress caused by CRS.
• Infection Screening: Screening for active infections (including tuberculosis or chronic viral infections) may be required before starting.

Do’s and Don’ts

• DO take all of your pre-medications exactly as directed by your doctor before each daily infusion.
• DO report any fever, severe nausea, or rash to your medical team immediately.
• DON’T get any live vaccines for up to a year after completing your 14-day treatment.
• DON’T miss your daily infusion appointments; completing all 14 consecutive days is vital for the drug to work properly.

Frequently Asked Questions

References

• U.S. Food and Drug Administration (FDA) – Tzield (teplizumab-mzwv) prescribing information.
• Drugs@FDA Overview – Tzield.
• American Diabetes Association (ADA) – Standards of Medical Care in Diabetes.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider regarding medical conditions or treatment plans.